Inovio Pharmaceuticals Inc Stock NYSE
Stocks
US45773H1023
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 97.08M 84.92M 78.33M 72.34M 137M 9.26B 140M 936M 368M 4.56B 365M 357M 15.68B | P/E 2026 * |
-1.32x | P/E 2027 * | -3.06x |
|---|---|---|---|---|---|
| Enterprise Value | 97.08M 84.92M 78.33M 72.34M 137M 9.26B 140M 936M 368M 4.56B 365M 357M 15.68B | EV / Sales 2026 * |
8.92x | EV / Sales 2027 * | 1.41x |
| Free-Float |
99.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Inovio Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 60 | 2022-05-09 |
Peter Kies
DFI | Director of Finance/CFO | 62 | 2002-05-31 |
| Chief Tech/Sci/R&D Officer | - | 2007-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 81 | 2019-01-02 |
Lota Zoth
BRD | Director/Board Member | 66 | 2017-12-31 |
Jay Shepard
BRD | Director/Board Member | 68 | 2020-01-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +2.06% | +3.90% | +10.40% | 50.73B | |
| -2.22% | -1.25% | +391.53% | +591.38% | 39.73B | |
| -0.54% | +0.39% | +27.67% | -3.89% | 34.69B | |
| -1.36% | +0.35% | +19.34% | +58.83% | 33.21B | |
| +1.21% | -4.58% | +3.00% | +37.03% | 26.76B | |
| -1.81% | -1.48% | - | - | 16.8B | |
| +0.51% | -3.47% | +66.38% | +125.61% | 15.37B | |
| +0.23% | -0.58% | +13.80% | +19.56% | 13.78B | |
| -0.62% | -3.09% | +11.43% | -29.93% | 12.85B | |
| Average | -0.45% | -0.83% | +67.13% | +101.12% | 27.1B | |
| Weighted average by Cap. | -0.48% | -0.23% | +82.75% | +126.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.88M 9.52M 8.78M 8.11M 15.38M 1.04B 15.64M 105M 41.19M 511M 40.85M 39.96M 1.76B | 69.07M 60.42M 55.73M 51.47M 97.67M 6.59B 99.31M 666M 261M 3.25B 259M 254M 11.16B |
| Net income | -68.56M -59.97M -55.32M -51.09M -96.94M -6.54B -98.57M -661M -260M -3.22B -257M -252M -11.07B | -45.76M -40.03M -36.92M -34.1M -64.7M -4.36B -65.79M -441M -173M -2.15B -172M -168M -7.39B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
